# Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease

> **NCT00267722** · PHASE2 · COMPLETED · sponsor: **Facet Biotech** · enrollment: 18 (—)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Visilizumab

## Key facts

- **NCT ID:** NCT00267722
- **Lead sponsor:** Facet Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 18 (—)
- **Last updated:** 2012-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00267722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00267722, "Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00267722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*